Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19.
Diabetes Obes Metab. 2020 May 29;:
Authors: Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, Qiu K, Zhang J, Zeng T, Chen L, Zheng J
CONTEXT: No studies evaluated the prospective association between hyperglycemia assessed by laboratory measurements and the risk of mortality among patients with coronavirus disease 2019 (COVID-19).
OBJECTIVE: We aimed to evaluate the association between different degrees of hyperglycemia and the risk of all-cause mortality among hospitalized patients with COVID-19.
DESIGN: A retrospective study.
SETTING: Union Hospital in Wuhan, China.
PARTICIPANTS: 453 patients were admitted to the hospital with laboratory-confirmed SARS-Cov-2 infection from January 22, 2020 to March 17, 2020.
MAIN OUTCOMES AND MEASURES: Patients were classified into four categories: normal glucose, hyperglycemia (fasting glucose 5.6-6.9 mmol/L and/or HbA1c 5.7-6.4%), newly diagnosed diabetes (fasting glucose ≥7 mmol/L and/or HbA1c ≥6.5%), and known diabetes. The major outcomes included in-hospital mortality, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV).
RESULTS: Patients with newly diagnosed diabetes had the highest percentage to be admitted to the ICU (11.7%) and require IMV (11.7%), followed by patients with known diabetes (4.1%; 9.2%) and patients with hyperglycemia (6.2%; 4.7%), compared with patients with normal glucose (1.5%; 2.3%), respectively. The multivariable-adjusted hazard ratios of mortality among COVID-19 patients with normal glucose, hyperglycemia, newly diagnosed diabetes, and known diabetes were 1.00, 3.29 (95% confidence interval [CI] 0.65-16.6), 9.42 (95% CI 2.18-40.7), and 4.63 (95% CI 1.02-21.0), respectively.
CONCLUSION: We firstly showed that COVID-19 patients with newly diagnosed diabetes had the highest risk of all-cause mortality compared with COVID-19 patients with known diabetes, hyperglycemia and normal glucose. Patients with COVID-19 need to be under surveillance for blood glucose screening. This article is protected by copyright. All rights reserved.
PMID: 32469464 [PubMed - as supplied by publisher]